Lexagene Holdings (Lexagene Holdings) Total Current Assets : $2.30 Mil (As of Nov. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Lexagene Holdings Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Lexagene Holdings's total current assets for the quarter that ended in Nov. 2022 was $2.30 Mil.

Lexagene Holdings Total Current Assets Historical Data

The historical data trend for Lexagene Holdings's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexagene Holdings Total Current Assets Chart

Lexagene Holdings Annual Data

Trend

Mar13

Mar14

Mar15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Total Current Assets

Get a 7-Day Free Trial

2.97

0.94

3.47

11.12

6.57

Lexagene Holdings Quarterly Data
	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22
Total Current Assets	Get a 7-Day Free Trial															3.66	6.57	4.64	2.87	2.30

Lexagene Holdings Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Lexagene Holdings's Total Current Assets for the fiscal year that ended in Feb. 2022 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	4.723	+	0.014	+	1.396	+	0.44
	=	6.57

Lexagene Holdings's Total Current Assets for the quarter that ended in Nov. 2022 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.464	+	0.052	+	1.445	+	0.335
	=	2.30

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Lexagene Holdings (OTCPK:LXXGQ) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Lexagene Holdings's Liquidation Value for the quarter that ended in Nov. 2022 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.464	-	2.217	+	0.75 * 0.052	+	0.5 * 1.445
=	-0.99

Lexagene Holdings Total Current Assets Related Terms

Thank you for viewing the detailed overview of Lexagene Holdings's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Lexagene Holdings (Lexagene Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lexagene Holdings Inc (OTCPK:LXXGQ) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Cummings Center, Suite 4550, Beverly, MA, USA, 01915

Website

https://www.lexagene.com

Lexagene Holdings Inc is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The MiQLab system delivers sensitivity, specificity, and breadth of detection and can return results in approximately two hours. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.